Ibrutinib Discontinuation in Waldenström Macroglobulinemia: Etiologies, Outcomes, and IgM Rebound

American Journal of Hematology - United States
doi 10.1002/ajh.25023
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Waldenström Macroglobulinemia

2020English

Spotting the Elusive Siberian Tiger: Complete Response to Ibrutinib in a Patient With Waldenström Macroglobulinemia

American Journal of Hematology
Hematology
2018English

A Head-To-Head Phase 3 Study Comparing BGB-3111 and Ibrutinib in Patients With Waldenström Macroglobulinemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

The Bone Marrow Microenvironment in Waldenström Macroglobulinemia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Waldenström Macroglobulinemia: Review of Pathogenesis and Management

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

Predictors of Symptomatic Hyperviscosity in Waldenström Macroglobulinemia

American Journal of Hematology
Hematology
2018English

CNS Vasculitis Associated With Waldenström Macroglobulinemia

Case Reports in Neurological Medicine
2016English

A 50-Year-Long Study of Waldenström Macroglobulinemia

Mayo Clinic Proceedings
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy